Glenmark Pharmaceuticals’ arm to launch Micafungin for Injection
The company will begin distribution in September 2025
Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA is planning to launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark’s Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA and the company will begin distribution in September 2025.
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
